Omeros/OMER

-4.34%
-
1D1W1MYTD1YMAX

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.

Ticker

OMER

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Gregory Demopulos

Employees

198

Headquarters

Seattle, United States

Omeros Metrics

BasicAdvanced
US$200M
Market cap
-
P/E ratio
-US$1.97
EPS
1.36
Beta
-
Dividend rate
US$200M
1.36291
US$7.80
US$0.92
394K
4.757
-5.39%
-35.9%
-44.81%
0.06%

What the Analysts think about Omeros

Analyst Ratings

Majority rating from 3 analysts.
Hold

Price Targets

Average projection from 1 analyst.
1,203.03% upside
High US$43.00
Low US$43.00
US$3.30
Current price
US$43.00
Average price target

Omeros Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
US$0
NaN%
Net income
-US$37M
312.22%
Profit margin
0%
NaN%

Omeros Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 8.5%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-US$0.59
-US$0.60
-US$0.15
-US$0.63
-
Expected
-US$0.57
-US$0.62
-US$0.56
-US$0.58
-US$0.67
Surprise
3.75%
-2.49%
-72.97%
8.5%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Omeros stock?

Omeros (OMER) has a market cap of $200M as of May 20, 2024.

What is the P/E ratio for Omeros stock?

The price to earnings (P/E) ratio for Omeros (OMER) stock is 0 as of May 20, 2024.

Does Omeros stock pay dividends?

No, Omeros (OMER) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next Omeros dividend payment date?

Omeros (OMER) stock does not pay dividends to its shareholders.

What is the beta indicator for Omeros?

Omeros (OMER) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Omeros stock price target?

The target price for Omeros (OMER) stock is $43, which is 1203.03% above the current price of $3.3. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Omeros stock

Buy or sell Omeros stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing